Dose optimisation: A strategy to improve tolerability and lower antiretroviral drug prices in low and middle income countries

Open Infectious Diseases Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 85-91

  Hill, Andrew ^a   Ananworanich, Jinatanat ^b   Calmy, Alexandra ^c,d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Developing countries; Health economics; HIV clinical trials; HIV RNA; Non nucleosides; Nucleoside analogues; Pharmacology; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PLACEBO; RALTEGRAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; DEVELOPING COUNTRY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOCIOECONOMICS;

EID: 78249258110     PISSN: None     EISSN: 18742793     Source Type: Journal    
DOI: 10.2174/1874279301004020085     Document Type: Article

References (34)

1. UNAIDS, WHO, UNICEF: TOWARDS UNIVERSAL ACCESS: Scaling up priority HIV/AIDS interventions in the health sector. Update 2009. Available on-line at: http: //www.who.int/hiv/pub/tu apr_2009_en.pdf [Accessed 2009].
2. Mugenyi P. Flat-line funding for PEPFAR: a recipe for chaos. Lancet 2009; 374: 292.
3. th ed. Pre-publication price analysis-2009. Available online at: http://www.msfaccess.org/file admin/user_upload/diseases/hiv-aids/Untangling_the_Web/Untangl ingtheWeb12_prepublicationpriceanalysis_July09pdf.pdf [Accessed October 2009].
4. President's Emergency Programme for AIDS Relief (PEPFAR). Summary Table of number treated for HIV. Available online at: http: //www.pepfar.gov/about/tables/treatment/123461.htm [Accessed 2009].
5. Clinton HIV-AIDS Initiative. Antiretroviral price list 2009. Available on-line at: http: //www.clintonfoundation.org/files/chai arvpricelistaugust2009english.pdf [Accessed 2009].
6. Pinheiro E, Vasan A, Kim J, Lee E, Guimier J, Perriens J. Examining the production costs of antiretroviral drugs. AIDS 2006; 20(13): 1745-52.
7. Volberding P, Lagakos S, Koch S et al. Zidovudine in asymptomatic HIV infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimetre. N Engl J Med 1990; 322: 941-9.
8. Kahn J, Lagakos S, Richman D, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581-7.
9. Hill A, Ruxrungtham K, Hanvanich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8 (5): 1-10.
10. World Health Organisation. Addendum to 2006 HIV Treatment Guidelines. Available at: http: //www.who.int/hiv/art/ARTadultsad dendum.pdf [Accessed 2009].
11. th International Conference on Retroviruses and Opportunistic Infections, Los Angeles, USA, 2007. Oral abstract 144LB. http://www. retroconference.org/2007/Abstracts/30659.htm
12. Lennox J, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial. Lancet 2009; 374: 796-806.
13. th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA 2008 [abstr. 788].
14. th International symposium on HIV infection, Bangkok, Thailand 2008.
15. Markowitz M, Morales-Ramirez J, Nguyen B, et al. Antiretroviral activity, pharmacokinetics and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment naïve HIV-1 infected individuals. J Acquir Immun Defic Syndr 2006; 43: 509-15.
16. Markowitz M, Nguyen B, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection. J Aquir Immun Defic Syndr 2007; 46: 125-33.
17. Grinsztejn B, Nguyen B, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment experienced patients with multidrug-resistant virus: a Phase II randomized controlled trial. Lancet 2007; 369: 1261-9.
18. th IAS Conference on HIV Pathogenesis, Cape Town, South Africa 2009 [abstr 2124].
19. Iwamoto M, Wenning L, Petry A, et al. Safety, tolerability and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharm Ther 2008; 83: 293-9.
20. Hammer S, Eron J, Reiss P, et al. Antiretroviral treatment of Adult HIV infection. 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300(5): 555-70.
21. th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998 [abstract 698).
22. ENCORE Trial. Available on www.clinicaltrials.gov. Accessed 2010. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT01011413?term=efavirenz&rank=31
23. Haas D, Ribaudo H, Kim R, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400.
24. Burger D, van der Helden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transciptase inhibitor efavirenz: the effect of gender, race and CYP2D6 polymorphism. Br J Pharmacol 2006: 61(2), 148-54.
25. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001; 15: 71-5.
26. Klein C, Chiu Y, Awni W, Zhu T, Heuser R, Doan T. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007; 44: 401-10.
27. th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, USA 2008 [abstr P37].
28. Flexner C, Chiu Y-L, Foit C, et al. Steady-state pharmacokinetics and short-term virologic response to two lopinavir-ritonavir (LPV/r) high-dose regimens in multiple antiretroviral experienced subjects (Study 049). Second IAS Conference on HIV Pathogenesis and Treatment, Paris France 2003 [Abstr 843].
29. Murphy R, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48 week results. AIDS 2001; 15: 1-9.
30. Johnson M, Gathe J, Podzdamczer D, et al. A Once-daily lopinavirritonavir based regimen provides non-inferior antiviral activity compared with a twice daily regimen. J Acquir Immun Defic Syndr 2006; 43, 153-60.
31. Meynard J, Lacombe K, Poirier J, et al. Virological Efficacy and Impact on Lipids Profile of a Reduced Dosing (2 tablets BID) of Lopinavir/Ritonavir (LPV/r) in HIV Infected Patients. (Kaledose Trial). 46th ICAAC September 2006, San Francisco, USA 2006 [abstr H-1384].
32. Van der Lugt J, Autar RS, Ubolyam S, et al. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J Antimicrob Chemother 2008; 61(5): 1145-53.
33. Hill A, Van der Lugt J, Boffito M. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS 2009 [e-published ahead of print].
34. Hill A, Sabin C. Designing and interpreting HIV noninferiority trials in naïve and experienced patients. AIDS 2008; 22: 913-21.